Compare · EW vs MYO
EW vs MYO
Side-by-side comparison of Edwards Lifesciences Corporation (EW) and Myomo Inc. (MYO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both EW and MYO operate in Industrial Specialties (Health Care), so they compete in similar markets.
- EW is the larger of the two at $50.30B, about 1017.1x MYO ($49.5M).
- Over the past year, EW is up 16.1% and MYO is down 44.1% - EW leads by 60.3 points.
- MYO has been more active in the news (10 items in the past 4 weeks vs 4 for EW).
- EW has more recent analyst coverage (25 ratings vs 3 for MYO).
- Company
- Edwards Lifesciences Corporation
- Myomo Inc.
- Price
- $87.45+0.92%
- $1.28-11.07%
- Market cap
- $50.30B
- $49.5M
- 1M return
- +6.41%
- +44.87%
- 1Y return
- +16.14%
- -44.13%
- Industry
- Industrial Specialties
- Industrial Specialties
- Exchange
- NYSE
- AMEX
- IPO
- 2017
- News (4w)
- 4
- 10
- Recent ratings
- 25
- 3
Edwards Lifesciences Corporation
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve replacement; aortic heart valves; annuloplasty rings; cardiac cannula devices; beating heart mitral valve repair system for the treatment of degenerative mitral regurgitation, as well as various procedure-enabling platforms to advance minimally invasive surgery. In addition, it offers critical care products, such as hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; pulmonary artery catheters; arterial pressure monitoring products, oximetry central venous catheters, as well as monitoring platforms that display a patient's physiological information; and Acumen Hypotension Prediction Index, which alerts clinicians in advance of a patient developing low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Myomo Inc.
Myomo, Inc., a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient's weak or paralyzed arm to enable and improve functional activities of daily living. Its products are designed to restore function in adults and adolescents with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury, and other neurological disorders. The company sells its products to orthotics and prosthetics providers, the Veterans Health Administration, and rehabilitation hospitals, as well as through distributors. Myomo, Inc. was incorporated in 2004 and is headquartered in Boston, Massachusetts.
Latest EW
- CEO Zovighian Bernard J sold $45,982 worth of shares (523 units at $87.92) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 11-K filed by Edwards Lifesciences Corporation
- SEC Form 11-K filed by Edwards Lifesciences Corporation
- SEC Form 3 filed by new insider Mistras Theodora
- SVP, Corporate Controller Dahl Andrew M. sold $48,853 worth of shares (568 units at $86.08), decreasing direct ownership by 4% to 15,334 units (SEC Form 4)
- CVP,Strategy/Corp Development Bobo Donald E Jr sold $2,000,193 worth of shares (23,145 units at $86.42) (SEC Form 4)
- SEC Form SD filed by Edwards Lifesciences Corporation
- CVP, TMTT & Surgical Chopra Daveen sold $126,905 worth of shares (1,500 units at $84.60), decreasing direct ownership by 3% to 44,324 units (SEC Form 4)
- CVP, TAVR Lippis Daniel J. exercised 620 shares at a strike of $72.68 and sold $50,307 worth of shares (620 units at $81.14) as part of a pre-agreed trading plan (SEC Form 4)
- CVP,Strategy/Corp Development Bobo Donald E Jr sold $1,472,678 worth of shares (17,968 units at $81.96), decreasing direct ownership by 30% to 22,798 units (SEC Form 4)
Latest MYO
- Myomo Announces Participation in iAccess Alpha Virtual Best Ideas Summer Investment Conference
- Chief Medical Officer Kovelman Harry covered exercise/tax liability with 10,442 shares, decreasing direct ownership by 10% to 90,541 units (SEC Form 4)
- Chief Commercial Officer Mitchell Micah covered exercise/tax liability with 9,061 shares, decreasing direct ownership by 9% to 93,888 units (SEC Form 4)
- Chief Financial Officer Henry David A covered exercise/tax liability with 10,969 shares, decreasing direct ownership by 3% to 424,155 units (SEC Form 4)
- Chief Commercial Officer Mitchell Micah covered exercise/tax liability with 6,529 shares, decreasing direct ownership by 6% to 102,949 units (SEC Form 4)
- Chief Medical Officer Kovelman Harry covered exercise/tax liability with 7,635 shares, decreasing direct ownership by 7% to 100,983 units (SEC Form 4)
- Chief Financial Officer Henry David A covered exercise/tax liability with 10,050 shares, decreasing direct ownership by 2% to 435,124 units (SEC Form 4)
- Director Kirk Thomas F bought $50,803 worth of shares (40,002 units at $1.27), increasing direct ownership by 6% to 693,865 units (SEC Form 4)
- Amendment: Chief Commercial Officer Mitchell Micah sold $77,689 worth of shares (90,231 units at $0.86), decreasing direct ownership by 45% to 109,478 units (SEC Form 4)
- Director Kirk Thomas F bought $24,825 worth of shares (25,000 units at $0.99), increasing direct ownership by 4% to 653,863 units (SEC Form 4)